Critical Insights From Moderna Analyst Ratings: What You Need To Know
Critical Insights From Moderna Analyst Ratings: What You Need To Know
来自Moderna分析师评级的关键见解：你需要知道的
Across the recent three months, 7 analysts have shared their insights on Moderna (NASDAQ:MRNA), expressing a variety of opinions spanning from bullish to bearish.
在最近三个月中，7位分析师分享了他们对Moderna（纳斯达克股票代码：MRNA）的见解，表达了从看涨到看跌的各种观点。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的评级，展示了过去30天情绪的演变，并将其与前几个月进行了比较。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $123.43, a high estimate of $231.00, and a low estimate of $69.00. Highlighting a 21.76% decrease, the current average has fallen from the previous average price target of $157.75.
分析师12个月目标股价的见解已经公布，平均目标股价为123.43美元，最高估计为231.00美元，低估值为69.00美元。当前的平均价格已从之前的157.75美元的平均目标股价下跌，这凸显了21.76％的跌幅。
Investigating Analyst Ratings: An Elaborate Study
调查分析师评级：一项详尽的研究
An in-depth analysis of recent analyst...
对分析师近期行...
登录免费看全文
登录/注册